首页 > 抗体蛋白 > 抗体
FITC anti-human HLA-DR Antibody
产品名称:
FITC anti-human HLA-DR Antibody
产品类别:
抗体
产品编号:
307603
产品应用:
307603
[价格]
规格 价格 库存
25tests ¥ 732 1

产品详情

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
African Green, Baboon, Chimpanzee, Dog, Common Marmoset, Squirrel Monkey, Cotton-topped Tamarin
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
test size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
?g size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
?g sizes: 0.5 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

For flow cytometric staining using the ?g size, the suggested use of this reagent is ≤2.0 ?g per million cells in 100 ?l volume. For flow cytometric staining using test sizes, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The L243 monoclonal antibody reacts with the HLA-DR antigen, a member of MHC class II molecules. It does not cross react with HLA-DP and HLA-DQ. Clone L243 binds a conformational epitope on HLA-DRa which depends on the correct folding of the a? heterodimer.19

Additional reported applications (for the relevant formats) include: immunoprecipitation8, Western blotting8, in vitro blocking of mixed lymphocyte reactions9,10, depeletion of MHC class II cells7,?immunohistochemical staining of acetone-fixed frozen sections4,5, and spatial biology (IBEX)21,22. For sensitive functional assays, we recommend using the Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) (Cat. No. 307648, 307665 - 307669).

Application References

(PubMed link indicates BioLegend citation)
  1. Brodsky F. 1984. Immunogenetics 19:179.
  2. Robbins P, et al. 1987. Human Immunol. 18:301.
  3. Stites D, et al. 1986. Clin. Immunol. Immunopathol. 38:161.
  4. Warnke R, et al. 1980. J. Histochem. Cytochem. 28:771. (IHC)
  5. Engleman E, et al. 1981. P. Natl. Acad. Sci. USA 78:1791. (IHC)
  6. Zipf T, et al. 1981. Cancer Res. 41:4786.
  7. Goodier M, et al. 2000. J. Immunol. 165:139. (Depletion)
  8. Esser M, et al. 2001. J. Virol. 75:6173. (IP, WB)
  9. Kalka-Moll WM, et al. 2002. J. Immunol. 169:6149. (Block)
  10. Wang RF, et al. 1999. Science 284:1351. (Block)
  11. Zaba LC, et al. 2007. J. Exp. Med. 204:3183. PubMed
  12. Fujita H, et al. 2009. P. Natl. Acad. Sci. USA 106:21795. PubMed
  13. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  14. Goncalves RM, et al. 2010. Infect. Immun. 78:4763. PubMed
  15. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  16. Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC)
  17. Stein R, et al. 2011. Leuk. Lymphoma 52:273.
  18. Galkowska H, et al. 1996. Vet. Immunol. Immunopathol. 53:329.
  19. Moro M, et al. 2005. BMC Immunol. 6:24.
  20. Lauterbach N, et al. 2014. Mol Immunol. 59:19. PubMed
  21. Radtke AJ,?et al. 2020.?Proc Natl Acad Sci USA. 117:33455-33465. (SB)?PubMed
  22. Radtke AJ,?et al. 2022.?Nat Protoc. 17:378-401. (SB)?PubMed
Product Citations
  1. Le Voyer T, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  2. Lathrop S, et al. 2015. Infect Immun . 83: 2661 - 2671. PubMed
  3. Manukyan G, et al. 2020. Auto Immun Highlights. 11:5. PubMed
  4. Tu S, et al. 2020. Cellular Signalling. 73:109695. PubMed
  5. Rochat MA, et al. 2018. Virol J. 15:191. PubMed
  6. Oshchepkova A, et al. 2019. Micromachines (Basel). 0.9375. PubMed
  7. Wang M, et al. 2022. Immun Inflamm Dis. 10:e626. PubMed
  8. Neuser J, et al. 2017. PLoS One.. 10.1371/journal.pone.0183670. PubMed
  9. Das J, et al. 2021. Med (N Y). 2:1269. PubMed
  10. Santiago K, et al. 2016. Pathog Dis. 74: ftw081. PubMed
  11. Zhou Y, et al. 2017. Front Cell Infect Microbiol. 7:457. PubMed
  12. Yoshimi A, et al. 2019. Nature. 574:273. PubMed
  13. Li J, et al. 2021. Front Cell Dev Biol. 9:737242. PubMed
  14. Li J, et al. 2022. Int J Mol Sci. 23:. PubMed
  15. Fang W,et al. 2017. PLoS One. 10.1371/journal.pone.0187088. PubMed
  16. Xia Y, et al. 2019. Gastroenterol Res Pract. 2019:5436961. PubMed
  17. Muenchhoff M, et al. 2016. Sci Transl Med. 8: 358ra125. PubMed
  18. Wang B, et al. 2017. Stem Cell Res Ther.. 10.1186/s13287-017-0744-6. PubMed
  19. Yan K, et al. 2022. iScience. 25:104822. PubMed
  20. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
  21. Ren K, et al. 2022. Brain Behav. 12:e2456. PubMed
  22. Germundson DL, et al. 2022. Front Allergy. 3:870513. PubMed
  23. Fraccarollo D, et al. 2021. eLife. 0.416666666666667. PubMed
  24. Port JR, et al. 2020. J Virol. 94:. PubMed
  25. J?ntvedt J?rgensen M, et al. 2021. Front Cell Infect Microbiol. 11:669623. PubMed
  26. Wang C, et al. 2020. Oncologist. 25:382. PubMed
  27. Khosravi-Maharlooei M, et al. 2021. J Autoimmun. 119:102612. PubMed
  28. Chao Y, et al. 2014. J Leukoc Biol. 96:1037. PubMed
  29. Gadd V, et al. 2016. PLoS One. 11: 0157771. PubMed
  30. Keshtkar S, et al. 2021. Stem Cells Int. 8857457:2020. PubMed
  31. Serrano-Villar S, et al. 2016. PLoS Pathog. 12: 1005381. PubMed
  32. Planès R, et al. 2014. J Virol. 88:6672. PubMed
  33. Iida H, et al. 2008. J Dermatol Sci. 52:31. PubMed
  34. Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed
  35. Hsieh J, et al. 2013. Nucleic Acids Res. 41:9753. PubMed
  36. He Z, et al. 2020. J Exp Clin Cancer Res. 39:140. PubMed
  37. Ran Y, et al. 2022. Stem Cell Res Ther. 13:507. PubMed
  38. Menges D, et al. 2022. Nat Commun. 13:4855. PubMed
  39. Wang X, et al. 2012. J Immunol. 189:3092. PubMed
  40. Collison J, et al. 2015. J Immunol. 195: 1162-1170. PubMed
  41. Sade-Feldman M, et al. 2016. Clin Cancer Res. 22(23):5661-5672. PubMed
  42. Lee PC, et al. 2022. J Clin Invest. 132:. PubMed
  43. Tang X, et al. 2020. Sci Adv. 6:eaaz0374. PubMed
  44. Shan L, et al. 2017. Immunity. 47:766. PubMed
RRID
AB_314681 (BioLegend Cat. No. 307603) AB_314682 (BioLegend Cat. No. 307604) AB_1089142 (BioLegend Cat. No. 307632)

Antigen Details

Structure
Ig superfamily, MHC class II, heterodimeric transmembrane protein, 36 kD heavy and 27 kD light chain
Distribution

B cells, activated T cells, monocytes/macrophages, dendritic cells, other APCs

Function
Peptide presentation
Ligand/Receptor
CD3/TCR, CD4
Cell Type
Antigen-presenting cells, B cells, Dendritic cells, Macrophages, Monocytes, T cells, Tregs
Biology Area
Immunology, Innate Immunity
Molecular Family
MHC Antigens
Antigen References

1. Levacher M, et al. 1990. Clin. Exp. Immunol. 81:177.
2. Terstappen L, et al. 1990. J. Leukocyte Biol. 48:138.
3. Edwards JA, et al. 1986. J. Immunol. 137:490.
4. van Es A, et al. 1984. Transplantation 37:65.
5. O'Doherty U, et al. 1994. Immunology 82:487.
6. Thomas R, et al. 1994. J. Immunol. 153:4016.
7. Grouard G, et al. 1996. Nature 384:364.

Gene ID
3122 View all products for this Gene ID 3123 View all products for this Gene ID
UniProt
View information about HLA-DR on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线